Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uric acid measurement (procedure)
|
1463 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.800 | 1.000 | 14 | 2008 | 2019 | |||||
Gout
|
2354 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.820 | 1.000 | 12 | 2008 | 2019 | |||||
Arthritis, Gouty
|
2356 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.810 | 1.000 | 11 | 2008 | 2019 | |||||
Hyperuricemia
|
76 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.800 | 1.000 | 10 | 2010 | 2019 | |||||
Malignant Neoplasms
|
1641 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.040 | 1.000 | 4 | 2005 | 2019 | |||||
Primary malignant neoplasm
|
1374 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.040 | 1.000 | 4 | 2005 | 2019 | |||||
Diarrhea
|
63 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.030 | 1.000 | 3 | 2006 | 2019 | |||||
Metabolic Syndrome X
|
591 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.030 | 1.000 | 3 | 2013 | 2019 | |||||
Neoplasms
|
1644 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.020 | 1.000 | 2 | 2005 | 2019 | |||||
Coronary Artery Disease
|
1577 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Kidney Calculi
|
71 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Multiple Myeloma
|
865 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Nephrolithiasis
|
99 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Obesity
|
1111 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Primary gout
|
5 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Secondary malignant neoplasm of lymph node
|
188 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Myeloid Leukemia, Chronic
|
115 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.040 | 1.000 | 4 | 2013 | 2018 | |||||
Epilepsy
|
339 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.020 | 1.000 | 2 | 2016 | 2018 | |||||
Kidney Failure, Chronic
|
425 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Lesch-Nyhan Syndrome
|
32 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Malignant neoplasm of stomach stage IV
|
7 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Nausea
|
14 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Rheumatoid Arthritis
|
2387 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Skin toxicity
|
24 | 0.583 | 0.680 | 4 | 88131171 | missense variant | G/C;T | snv | 4.0E-06; 0.12 | 0.010 | 1 | 2018 | 2018 |